+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

This research aims to evaluate intestinal Levodopa plus entacapone therapy Lecigon4 in patients with Parkinsons disease who require this treatment based on existing guidelines. The study is a Phase III randomized controlled trial comparing Lecigon4 to the best available oral medication. The primary goal is to assess whether Lecigon4 is superior in reducing hyperdopaminergic symptoms measured by the Ardouin Behavioral Scale after six months. Participants are randomly assigned to one of two groups those continuing best oral medication and those receiving Lecigon4 as an intestinal gel combining levodopa, carbidopa, and entacapone. The trial uses a parallel group design with a waiting list component. Treatment is given according to established dosing criteria and patients are followed for at least six months to monitor effects. During the study, participants undergo regular assessments including behavioral evaluations with the Ardouin Behavioral Scale to track hyperdopaminergic syndrome changes. Safety and adherence to therapy are monitored throughout. The trial excludes patients with severe cognitive impairment or other contraindications. Total participation covers screening, treatment, and follow-up up to six months, with the primary outcome measured at that time.

Age: 18Years - 75YearsAll GendersPhase 3
7 locations
R

Actively Recruiting

Parkinsons disease PD is a neurological disorder that worsens over time with symptoms like tremors, stiffness, and slow movement. This research evaluates how effective foscarbidopafoslevodopa is for German adults in the early stages of advanced PD. Approximately 125 adults prescribed this treatment by their physicians will participate in this observational study. Participants will receive foslevodopafoscarbidopa through subcutaneous infusion as directed by their doctors, following routine clinical practice. The study includes a follow-up period lasting up to 12 months to monitor treatment effects without adding extra burden to participants. During the study, participants will attend regular hospital or clinic visits as part of their usual care. Researchers will measure changes in OFF time hours up to 6 months to assess motor symptom improvements. The study will also look at quality of life and psychosocial functioning while monitoring participants throughout the year-long observation period.

Age: 18Years - 67YearsAll Genders
19 locations